OBJECTIVE： To systematically review the efficacy of Tangmaikang tablet combined with conventional hypolycemic agents in the treatment of diabetic kidney disease， and provide evidence-based reference for clinic. METHODS： Retrieved from Medline， EMBase， Cochrane Library， CBM， CJFD， Wanfang Database and VIP， randomized controlled trials （RCT） about Tangmaikang tablet combined with western medicine （test group） versus western medicine alone （control group） in the treatment of diabetic kidney disease were collected. Meta-analysis was performed by Rev Man software after data extraction and quality evaluation. RESULTS：Totally 9 RCTs were included， involving 883 patients. Results of Meta-analysis showed， the clinical effective rate in test group were significantly higher than control group [OR＝4.88，95％CI（2.56，9.32），P＜0.001]， Scr level[MD＝－28.48，95％CI（－34.90，22.06），P＜0.001] and 24 h urinary protein excretion [MD＝－100.26，95％CI（－106.00，－94.52），P＜0.001]， with statistical significance； there was no significant difference in BUN level in 2 groups [MD＝－0.85，95％CI（－1.36，－0.34），P＝0.001]. CONCLUSIONS： Tangmaikang granule/tablet combined with conventional hypoglycemic agents has good efficacy in the treatment of diabetic kidney disease， which can reduce patients’ Scr and 24 h urinary protein excretion.